Company: BIAF
Filing Date: 2025-09-30
Form Type: 424B4
Source: 0001493152-25-016338
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-30
Form: 424B4
Chunk 16
---
 per share information in this prospectus (other than in the historical financial statements incorporated herein by
reference) has been adjusted to reflect the reverse stock split.

If we are delisted from Nasdaq, but obtain a substitute listing for our Common Stock, it will likely be on a market with less liquidity, and therefore experience potentially more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares of Common Stock on any such substitute market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our Common Stock is delisted from Nasdaq, the value and liquidity of our Common Stock, warrants and pre-funded warrants would likely be significantly adversely affected. A delisting of our Common Stock from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a loss of confidence by investors, employees and/or business partners.

| 12 |

<div align='center'>USE OF PROCEEDS</div>

We estimate that the net proceeds from sale of shares of Common Stock (or Pre-Funded Warrants in lieu thereof) offered by us in this offering will be approximately $4.1 million, after deducting the Placement Agent fees and estimated offering expenses payable by us.

We intend to use the net proceeds of this offering for working capital and other general corporate purposes.

This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. Pending our application of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment grade, interest bearing instruments and U.S. government securities.

| 13 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our capitalization:

| ● 
 ● | on                                                                                                                                 
 an actual basis as of June 30, 2025;                                                                                               
 on                                                                                                                                 
 a pro forma basis to give effect to: (i) an aggregate of 21,666 shares of Common Stock that we issued on October 21, 2024 upon the 
 exercise of warrants, at the reduced exercise price of $6.90 per share, and our                                                    
 receipt of approximately $149,500 in proceeds upon such exercise, (ii) an aggregate of 15,000                                      
 shares of Common Stock that we issued on August 5, 2024, upon the exercise of warrants, at the reduced exercise price of $6